Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer

We herein report the case of a 79-year-old patient with unresectable stage III non-small cell lung cancer who developed immune-related hepatitis caused by durvalumab administration. Durvalumab was administered at 10 mg/kg every two weeks after the treatment with carboplatin (AUC2), paclitaxel (35 mg...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Intern Med
Hlavní autoři: Nakamura, Masakatsu, Otsuka, Toshimi, Hayashi, Ranji, Horita, Tomoe, Ota, Masafumi, Sakurai, Naoko, Takano, Hikaru, Hayashi, Tasuku, Kumagai, Motona, Yamada, Sohsuke, Arisawa, Tomiyasu
Médium: Artigo
Jazyk:Inglês
Vydáno: The Japanese Society of Internal Medicine 2020
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7691038/
https://ncbi.nlm.nih.gov/pubmed/32669493
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.4699-20
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky